Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain
This article was originally published in The Pink Sheet Daily
Executive Summary
Rep. Phil Gingrey, lead sponsor of the Generating Antibiotic Incentives Now Act, says industry still has questions about the proposed approval pathway for antibiotics treating life-threatening diseases, further clouding its prospects.
You may also be interested in...
Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.
FDA Acknowledges More Diverse Subgroup Data Needed In Trials
FDASIA-mandated report indicates some trials underrepresented some racial groups, but the agency says those subsets may not be the proper groupings in the era of personalized medicine.
CDER Adds Antibiotics Specialist For New Senior Advisor Role
Robert Guidos returns to FDA from the Infectious Diseases Society of America as senior advisor in the CDER Immediate Office of the Center Director, although the job description seems to indicate a focus beyond antimicrobial issues.